Is IDEAYA Biosciences Inc. [IDYA] Stock Is Still Just for Futuristic Bulls at this Point?

Over the past three months, IDEAYA Biosciences Inc. [IDYA] ended the trading day at $17.43 and exhibited a change of 11.74% with a 24 hour trading and reached upto the volume of 167.32K compared to its recorded trading volume of 0.35 million. IDYA generated a 1 year amount change with 97.72%. Though for Principal markets a year is counted as a long time period. By having a look at the most recent performance of this stock, in the last week its amount moved by 15.04% with an amount shift of 18.36% over the last month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 12, November 2020, IDEAYA Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update. According to news published on Yahoo Finance, – IDE397, a potential best-in-class MAT2A inhibitor for patients with solid tumors having MTAP deletion, targeting an IND-filing in December 2020.

Analyst Birdseye View:

The most recent analyst activity for IDEAYA Biosciences Inc. [NASDAQ:IDYA] stock was on September 01, 2020, when it was Initiated with an Outperform rating from Northland Capital, which also raised its 12-month price target on the stock to $28. Before that, on October 07, 2020, Wedbush Recapitulated an Outperform rating and elevated its amount target to $21. On July 13, 2020, JP Morgan Upgrade an Overweight rating and boosted its price target on this stock to $28. On June 17, 2020, H.C. Wainwright Reiterated a Buy rating and increased its price target from $13 to $22. On April 06, 2020, H.C. Wainwright Initiated a Buy rating and increased its price target to $13. On March 13, 2020, ROTH Capital Initiated a Buy rating and boosted its amount on this stock to $12. On October 17, 2019, Oppenheimer Initiated an Outperform rating and boosted its target amount on this stock to $17.

In the past 52 weeks of trading, this stock has oscillated between a low of $2.95 and a peak of $19.97. Right now, according to Wall Street analyst the average 12-month amount target is $24.56. At the most recent market close, shares of IDEAYA Biosciences Inc. [NASDAQ:IDYA] were valued at $17.43. According to the average price forecast, investors can expect a potential return of -2.33%.


If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 6.32 and the whole liability to whole assets at 5.99. It shows enduring liability to the whole principal at 5.25 and enduring liability to assets at 0.05 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 14.51 points at 1st support level, the second support level is making up to 13.42. But as of 1st resistance point, this stock is sitting at 16.42 and at 17.24 for 2nd resistance point.

IDEAYA Biosciences Inc. [IDYA] reported its earnings at -$0.17 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at $1.13/share signifying the difference of -1.3 and -115.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.59 calling estimates for $1.83/share with the difference of -2.42 depicting the surprise of -132.20%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for IDEAYA Biosciences Inc. [NASDAQ:IDYA] is 5.20. Likewise, the Quick ratio is also the same, showing Cash ratio at 14.26. Now if looking for a valuation of this stock’s amount to book ratio is 1.52.

Insider Stories

The most recent insider trade was by 5AM Ventures IV, L.P., Former 10% holder, and it was the sale of 0.8 million shares on Nov 11. BVF PARTNERS L P/IL, the 10% Owner, completed a purchase of 2531.0 shares on Jun 30. On Jun 22, BVF PARTNERS L P/IL, 10% Owner, completed a purchase of 19732.0 shares.